Peptide-based immunotherapy in lupus: Where are we now?
Ram P Singh1, David S Bischoff1,2, Satendra S Singh3
1Research Service, Veteran Administration Greater Los Angeles Healthcare System, Los Angeles, 90073 CA, USA.
Rheumatology and Immunology Research
|October 2, 2023
Summary
Peptide-based therapies show promise for treating autoimmune rheumatic diseases by restoring immune balance. This review focuses on their application in lupus, a complex autoimmune condition.
Area of Science:
- Immunology
- Rheumatology
- Nanotechnology
Background:
- Autoimmune rheumatic diseases involve immune hyperactivity, chronic inflammation, and loss of self-tolerance.
- An imbalance between effector and regulatory immune responses worsens inflammation and causes organ damage.
- Current treatments aim to restore immune tolerance and balance.
Purpose of the Study:
- To review the current therapeutic applications of peptide-based treatments.
- To highlight the use of peptide therapies in autoimmune rheumatic diseases.
- To specifically focus on the efficacy of peptide-based treatments in lupus.
Main Methods:
- Literature review of peptide-based therapies.
- Analysis of studies on immune dysregulation in rheumatic diseases.
- Examination of nanotechnology in therapeutic development.
Main Results:
- Peptide-based therapeutics are a key area of development.
- Nanotechnology offers novel delivery systems for peptide therapies.
- Restoring immune self-tolerance is crucial for managing these diseases.
Conclusions:
- Peptide-based therapies represent a significant advancement in treating autoimmune rheumatic diseases.
- Further research into peptide applications, particularly for lupus, is warranted.
- Targeting immune dysregulation with advanced therapeutics holds therapeutic potential.
